Regulus Therapeutics demonstrates human proof-of-concept

Regulus Therapeutics Inc. (Nasdaq: RGLS) demonstrated human proof-of-concept with a microRNA therapeutic for its hepatitis C treatment RG-101. Shares of the biopharmaceutical nearly doubled by jumping $6.63 to $13.40.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.